TY  - JOUR 
AU  - Seijas Amigo, José
AU  - Salgado Barreira, Angel
AU  - Castelo Domínguez, Rosa Ana
AU  - Pérez-Álvarez, M.T.
AU  - Ponce-Piñón, B.
AU  - Fernández-Silva, M.
AU  - Rodríguez-Barreiro, M.
AU  - Pereira-Pía, M.
AU  - Iglesias-Moreno, J.M.
AU  - Gago-García, M.
AU  - Montáns-García, R.
AU  - Fernandez-Perez, A.
AU  - FragaGayoso, D.
AU  - Fernández Montenegro, Montserrat
AU  - Riveiro-Barciela, B.
AU  - Rilla-Villar, N.
AU  - Cordero, Alberto
AU  - RodríguezMañero, M.
AU  - González Juanatey, José Ramón
PY  - 2023
SN  - 1878-0210
UR  - http://hdl.handle.net/20.500.11940/21349
AB  - Introduction: Obesity increases the risk of type 2 diabetes mellitus and cardiovascular disease (CVD). Weight loss (?5 %) reduces the risk of CVD. Glucagon-like peptide-1 receptor agonists (GLP1 RA) have shown clinically weight loss. Objectives: 1) To...
LA  - eng
KW  - Humans
KW  - Female
KW  - Middle Aged
KW  - Male
KW  - Diabetes Mellitus, Type 2
KW  - Hypoglycemic Agents
KW  - Glycated Hemoglobin
KW  - Prospective Studies
KW  - Weight Loss
KW  - Glucagon-Like Peptide-1 Receptor Agonists
TI  - Differences in weight loss and safety between the glucagon-like peptide-1 receptor agonists: A non-randomized multicenter study from the titration phase
DO  - 10.1016/j.pcd.2023.05.004
T2  - Primary Care Diabetes
M2  - 366
KW  - AS Santiago
KW  - IDIS
KW  - AS Vigo
KW  - CHUVI
KW  - AS Santiago
KW  - AS Santiago AP
KW  - AS Ourense
KW  - CHUO
KW  - AS Santiago
KW  - IDIS
KW  - AS Santiago
KW  - CHUS
VL  - 17
ER  -